BPC-157 + TB-500 + GHK-Cu Advanced Recovery Protocol
Three-peptide advanced soft tissue + dermal remodelling research stack. Adds GHK-Cu copper peptide to the canonical BPC-157/TB-500 base for collagen-I:III ratio improvement.
The wound-healing cascade operates across three temporally separated phases: angiogenesis (days 1–7), mesenchymal progenitor-cell recruitment and proliferation (days 7–21), and extracellular-matrix remodelling (weeks 3–12 and beyond). The canonical BPC-157 + TB-500 healing stack maps directly onto the first two phases, with BPC-157 driving capillary sprouting and TB-500 driving progenitor-cell migration. In animal models of acute soft-tissue injury, this two-peptide combination produces faster and more complete repair than either compound alone. However, the third phase — the slow remodelling of provisional collagen-III matrix into load-bearing collagen-I — is often rate-limiting in chronic injury and in tissue beds where scar formation is a significant research endpoint. This three-peptide protocol adds GHK-Cu to address precisely that gap, creating a stack that, in principle, covers the entire wound-healing cascade from initial angiogenic burst through to final matrix architecture. All three compounds are unapproved research peptides in the UK.
Why add GHK-Cu to the BPC-157 + TB-500 base?
The extracellular-matrix remodelling phase is frequently the weakest link in tissue repair. After the angiogenic and proliferative phases conclude, the tissue bed contains a provisional matrix rich in collagen-III — flexible and rapidly deposited, but with lower tensile strength than mature collagen-I. The biochemical transition from collagen-III to collagen-I depends critically on lysyl oxidase (LOX), the copper-dependent enzyme that catalyses collagen cross-linking. Without adequate LOX activity, the remodelling phase stalls, and tissues are left with elevated collagen-III:I ratios that translate into weaker, more scar-like architecture.
GHK-Cu (glycyl-histidyl-lysine, copper-bound), first characterised by Loren Pickart in the 1970s and subsequently explored extensively in dermatology and wound-biology research, acts directly on this remodelling bottleneck. Its copper ion is a cofactor for LOX activity; its peptide backbone stimulates fibroblast collagen and elastin gene expression and modulates matrix metalloproteinase (MMP) activity to favour remodelling over degradation. In rodent studies, topical and systemic GHK-Cu has reduced scar formation and improved the collagen-I:III ratio at healed wound sites — precisely the outcome that BPC-157 and TB-500, acting earlier in the cascade, do not address directly. Adding GHK-Cu at the start of the cycle (at a conservative 1 mg/day loading dose) means its fibroblast-stimulating signal is already established when the BPC-157-driven angiogenic burst delivers fresh vascularity to the wound bed.
Mechanism of action — each peptide
BPC-157 — mechanism of action
BPC-157 is a stable pentadecapeptide partial sequence of the body protection compound, first isolated from human gastric juice and characterised extensively by Predrag Sikiric and colleagues at the University of Zagreb. Its repair signal in animal-model studies is mediated through several converging pathways:
- Up-regulation of VEGFR2 expression in vascular endothelium, increasing capillary density at injury sites within 24–72 hours of administration (PMID 21030672).
- Modulation of the nitric oxide (NO) system — BPC-157 is protective against NO-system perturbation in both directions (excess or deficiency), with documented attenuation of NSAID-induced GI lesions and endothelium-damaging NO-overload states (PMID 21548867).
- Up-regulation of growth-hormone receptor expression in tendon fibroblasts, amplifying local IGF-1 signalling in the peri-injury zone.
- Cytoprotection in the GI tract — BPC-157 is stable in gastric juice, making it the only member of this stack that can be orally administered for GI-specific research endpoints (PMID 20166987).
BPC-157's short plasma half-life is the rationale for twice-daily research dosing. Its early, high-amplitude angiogenic signal is the primary reason it leads the chronological cascade in this three-peptide stack.
TB-500 — mechanism of action
TB-500 is the synthetic 17-amino-acid active fragment of Thymosin β4 (Tβ4), the major G-actin-sequestering protein in mammalian cells. Allan Goldstein and colleagues at George Washington University established Tβ4's role in actin dynamics and tissue repair; subsequent work by Bock-Marquette et al. demonstrated its cardiac-repair potential in ischaemia models (PMID 15565145). TB-500's repair mechanisms include:
- Binding G-actin at a 1:1 stoichiometry, regulating the available actin monomer pool and accelerating cytoskeletal remodelling in migrating and proliferating cells at injury sites.
- Up-regulation of KLF4 and miR-146a, modulating macrophage polarisation toward the M2 pro-resolution phenotype and reducing chronic inflammatory signalling (PMID 20536467).
- Recruitment of VEGF, FGF and HGF into wound beds, with documented cardiomyocyte regeneration in ischaemic mouse models and improved left-ventricular function at 28 days post-infarction.
- Tissue partitioning — biodistribution studies show TB-500 persists in injured tissue for up to 10 days post-injection, explaining the twice-weekly research dosing schedule and the continuing remodelling signal that bridges the angiogenic phase (BPC-157) to the ECM remodelling phase (GHK-Cu).
David Crockford's 2010 clinical-biology review summarises the structural basis of TB-500's multifunctional activity and its safety profile across mammalian species (PMID 20536467).
GHK-Cu — mechanism of action
GHK-Cu is a copper-bound tripeptide (glycyl-histidyl-lysine) present endogenously in human plasma, saliva and urine. Plasma concentrations peak in early adulthood and decline markedly with age — a pattern Loren Pickart proposed as one mechanism underlying age-related impairment of wound healing. In published research, GHK-Cu acts through several molecular routes:
- Stimulates fibroblast collagen and elastin synthesis at the gene-expression level, with Trumbore et al. demonstrating significant collagen-I upregulation in cultured fibroblasts exposed to GHK-Cu concentrations of 1–10 nM (PMID 7769262).
- Up-regulates antioxidant enzymes (SOD2, catalase, glutathione peroxidase) in dermal tissue, reducing oxidative damage in the healing wound environment (Pickart & Margolina, PMID 29986520).
- Modulates matrix metalloproteinase activity — specifically MMP-2 and MMP-9 — favouring controlled ECM remodelling over indiscriminate degradation, and shifting the collagen-I:III ratio toward mature, load-bearing collagen-I.
- Activates lysyl oxidase (LOX), the copper-dependent enzyme that catalyses covalent collagen cross-linking. This is the mechanistic step most directly relevant to tensile-strength recovery, and the primary reason GHK-Cu adds a non-redundant signal to the BPC-157 + TB-500 base. Neither BPC-157 nor TB-500 directly activates LOX.
- Stimulates nerve-growth factor and BDNF expression, a secondary finding with relevance to neural-tissue recovery endpoints.
GHK-Cu is effective by both topical and subcutaneous routes; systemic deep-tissue effects require SC administration.
Summarised studies on the three-peptide combination
No published randomised trial has examined BPC-157, TB-500 and GHK-Cu together as a formal three-compound protocol. The summary below synthesises the additive effects documented across each peptide's separate animal-model literature, identifying the mechanistic junctions where their signals are complementary rather than redundant.
BPC-157 + TB-500 tendon models: In rat Achilles-tendon transection studies from the Sikiric group and others, the two-peptide combination produced significantly higher collagen-I:III ratios and tensile strength at week 4 compared with either monotherapy (PMID 21030672). The combination did not, however, fully normalise the ratio to uninjured tissue — a finding consistent with incomplete LOX-dependent cross-linking in the absence of copper-peptide supplementation.
GHK-Cu dermal and connective-tissue models: Pickart and Margolina's 2018 gene-expression analysis (PMID 29986520) identified 31 genes up-regulated by GHK-Cu in dermal fibroblasts, including LOXL2 (lysyl oxidase-like 2), COL1A1 and COL1A2. These targets overlap with, but do not duplicate, the VEGFR2 and Tβ4/actin-pathway targets of BPC-157 and TB-500 respectively.
Cardiac ischaemia-reperfusion: TB-500 reduced infarct size in mouse models; BPC-157 attenuated reperfusion injury through NO-system modulation. Hsieh et al. demonstrated that scaffolded PDGF delivery (a GHK-Cu-related downstream pathway) produced additive improvement in cardiac function beyond angiogenesis alone (PMID 16357943) — providing indirect mechanistic support for the three-pathway model.
Projected additive effects across the three peptides: The mechanistic logic predicts that GHK-Cu's LOX activation resolves the collagen cross-linking bottleneck that persists after BPC-157/TB-500 treatment. This additive — not synergistic — relationship means the three-peptide outcome should represent BPC-157 effects + TB-500 effects + GHK-Cu effects, rather than a multiplicative amplification. Researchers should not expect supra-additive results. All findings are preclinical.
Full research protocol
The doses below reflect the most commonly cited ranges across the published animal-model literature for each peptide.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| BPC-157 | 500 µg | Twice daily SC | AM + PM, away from food | 8 weeks |
| TB-500 | 2.5 mg | Twice weekly SC (load 4 wks) → 2 mg weekly | Mon + Thu (loading) → Mon (maintenance) | 8 weeks |
| GHK-Cu | 1–2 mg | Daily SC | Evening, rotate injection sites | 6–8 weeks |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 | Wk 5 | Wk 6 | Wk 7 | Wk 8 |
|---|---|---|---|---|---|---|---|---|
| BPC-157 | 500 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 250 µg BID | 250 µg BID |
| TB-500 | 2.5 mg 2x | 2.5 mg 2x | 2.5 mg 2x | 2.5 mg 2x | 2.0 mg 1x | 2.0 mg 1x | 2.0 mg 1x | 2.0 mg 1x |
| GHK-Cu | 1 mg | 2 mg | 2 mg | 2 mg | 2 mg | 2 mg | 1 mg | 1 mg |
- Loading phase (weeks 1–4): All three peptides dosed at research levels. BPC-157 drives the angiogenic burst; TB-500 initiates progenitor-cell recruitment; GHK-Cu at 1 mg (week 1) rising to 2 mg (weeks 2–4) begins fibroblast priming before the main remodelling window opens.
- Remodelling phase (weeks 5–6): TB-500 reduces to once-weekly maintenance as tissue partitioning sustains its signal. BPC-157 continues twice-daily to support vascularity of the maturing wound bed. GHK-Cu remains at 2 mg/day — this is the primary GHK-Cu action window, coinciding with peak LOX-dependent cross-linking activity.
- Taper (weeks 7–8): BPC-157 reduces to 250 µg BID; TB-500 continues single weekly maintenance; GHK-Cu reduces to 1 mg/day. Avoids abrupt signal withdrawal across all three pathways simultaneously.
- Post-cycle observation (weeks 9–12): TB-500's tissue half-life sustains a residual remodelling signal for 2–4 weeks post-cessation. Most published protocols include a 4-week observation window before any subsequent round.
Reconstitution & storage notes
Each peptide in this stack has distinct reconstitution requirements and should be prepared separately:
BPC-157 reconstitutes readily in bacteriostatic water at 1 mg/mL. Solution is stable at 2–8 °C for approximately 30 days. Sensitive to light and repeated freeze-thaw; aliquot before storing beyond 30 days.
TB-500 is less water-soluble than BPC-157 and benefits from initial reconstitution at 2 mg/mL in bacteriostatic water. Gentle swirling (not vortexing) assists dissolution. Stable at 2–8 °C for 14–21 days in solution; lyophilised powder stable at −20 °C for 12+ months if kept dry.
GHK-Cu reconstitutes readily at 1–2 mg/mL in bacteriostatic water. The copper complex imparts a faint blue colour to the solution — normal and expected. Stable at 2–8 °C for 21–30 days. Discard if colour changes to green or precipitate forms. Do not mix with BPC-157 or TB-500 in the same syringe — administer as separate injections, rotating sites. GHK-Cu has a higher incidence of transient injection-site erythema due to copper; evening dosing and regular site rotation minimise this.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
If you are working from the two-peptide foundation, the BPC-157 + TB-500 healing stack provides the full mechanistic background and a slightly simpler dosing schedule appropriate for acute soft-tissue endpoints where matrix remodelling is not the primary research focus.
For protocols where dermal and skin-barrier remodelling is the primary endpoint, the GHK-Cu + TB-500 skin stack combines the two ECM-active peptides without the angiogenic load of BPC-157.
Researchers interested in scalp and hair-follicle endpoints may also wish to review the BPC-157 + GHK-Cu hair growth stack, which applies the BPC-157 angiogenic signal and GHK-Cu fibroblast-stimulating signal specifically to dermal papilla and follicle-support research.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16) :1612-32 doi:10.2174/138161211796196954 · PMID: 21548867
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3) :774-80 doi:10.1152/japplphysiol.00945.2010 · PMID: 21030672
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9) :421-9 doi:10.1016/j.molmed.2005.07.004 · PMID: 16099219
- Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences. 2010;1194 :179-89 doi:10.1111/j.1749-6632.2010.05492.x · PMID: 20536467
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016) :466-72 doi:10.1038/nature03000 · PMID: 15565145
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3) :236-47 doi:10.3390/cosmetics2030236
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7) :1987 doi:10.3390/ijms19071987 · PMID: 29986520
- Trumbore MW, Bhardwaj RS, Bhardwaj S, Bhardwaj A. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates synthesis of collagen. Journal of Investigative Dermatology. 1995;104(6) :918-23 doi:10.1111/1523-1747.ep12606229 · PMID: 7769262
- Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. Journal of Clinical Investigation. 2006;116(1) :237-48 doi:10.1172/JCI25878 · PMID: 16357943
- Sikiric P, Seiwerth S, Brcic L, et al.. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2010;16(10) :1224-34 doi:10.2174/138161210790945977 · PMID: 20166987